Claims
- 1. A method for treating allergy symptoms in a patient, comprising the step of:
administering in a manner so as not to effect gene transfer an effective amount of DNA in a pharmaceutically-acceptable vehicle to a patient having allergy symptoms.
- 2. The method according to claim 1 wherein said DNA is administered sublingually in the form of a liquid drop.
- 3. The method according to claim 1 wherein said vehicle is selected from the group consisting of water, saline, albumin, or dextrose.
- 4. The method according to claim 1 wherein said effective amount of DNA is from about 0.00012 mg to about 0.003 mg DNA.
- 5. The method according to claim 1 wherein said effective amount of DNA is about 0.0006 mg of DNA.
- 6. The method according to claim 1 wherein said patient is a human.
- 7. The method of claim 1 wherein the DNA is administered by a route selected from the group consisting of sublingual, subcutaneous, intravenous, intramuscular and intrathecal administration.
- 8. A method for treating asthma symptoms in a patient, comprising the steps of:
administering in a manner so as not to effect gene transfer a therapeutically effective amount of DNA in a pharmaceutically-acceptable vehicle to a patient having asthma symptoms.
- 9. The method according to claim 8 wherein said DNA is administered sublingually in the form of a liquid drop.
- 10. The method according to claim 8 wherein said vehicle is selected from the group consisting of water, saline, albumin, or dextrose.
- 11. The method according to claim 8 wherein said effective amount of DNA is from about 0.00012 mg to about 0.003 mg DNA.
- 12. The method according to claim 8 wherein said effective amount of DNA is about 0.0006 mg of DNA.
- 13. The method according to claim 8 wherein said patient is a human.
- 14. The method of claim 8 wherein the DNA is administered by a route selected from the group consisting of sublingual, subcutaneous, intravenous, intramuscular and intrathecal administration
- 15. A method for treating symptoms of otitis media, comprising the step of:
topically administering in a manner so as not to effect gene transfer an effective amount of DNA in a pharmaceutically-acceptable vehicle to a patient having otitis media.
- 16. The method according to claim 15 wherein said vehicle is selected from the group consisting of water, saline, albumin, or dextrose
- 17. The method according to claim 15 wherein said effective amount of DNA is from about 0.00012 mg to about 0.003 mg DNA.
- 18. The method according to claim 15 wherein said effective amount of DNA is about 0.0006 mg of DNA.
- 19. The method according to claim 15 wherein said patient is a human.
- 20. The method of claim 15 wherein the DNA is administered in the form of eardrops.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/432,948 filed Nov. 3, 1999 which is a continuation-in-part of U.S. patent application Ser. No. 09/037,895 filed Mar. 10, 1998 which is a continuation-in-part of U.S. patent application Ser. No. 08/755,092 filed Nov. 22, 1996, issued Mar. 10, 1998 as U.S. Pat. No. 5,726,160 which is a continuation of U.S. patent application Ser. No. 08/421,232 filed Apr. 13, 1995.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09495186 |
Feb 2000 |
US |
Child |
10113771 |
Apr 2002 |
US |
Parent |
08421232 |
Apr 1995 |
US |
Child |
08755092 |
Nov 1996 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09432948 |
Nov 1999 |
US |
Child |
09495186 |
Feb 2000 |
US |
Parent |
09037895 |
Mar 1998 |
US |
Child |
09432948 |
Nov 1999 |
US |
Parent |
08755092 |
Nov 1996 |
US |
Child |
09037895 |
Mar 1998 |
US |